CEL-SCI Corp
CVM5.120USD
+4.916+2412.27%
Close 05/20, 16:00（ET）Quotes delayed by 15 min
431.87MMarket Cap
LossP/E TTM
More Details of CEL-SCI Corp Company
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Company Info
Company codeCVM
Company nameCEL-SCI Corp
IPO dateDec 08, 1983
Founded at1983
CEOMr. Geert R. Kersten, Esq.
Number of employees- -
Security typeOrdinary Share
Fiscal year-endDec 08
AddressSuite 802
CityVIENNA
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code22182
Phone17035069460
Websitehttps://cel-sci.com/
Company codeCVM
IPO dateDec 08, 1983
Founded at1983
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Geert R. Kersten, Esq.
Mr. Geert R. Kersten, Esq.
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
41.35K
+1.87%
Ms. Patricia B. Prichep
Ms. Patricia B. Prichep
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
8.87K
+6.15%
Dr. Eyal Talor, Ph.D.
Dr. Eyal Talor, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
4.50K
+8.36%
Mr. Robert Eugene (Bob) Watson
Mr. Robert Eugene (Bob) Watson
Independent Chairman of the Board
Independent Chairman of the Board
814.00
--
Mr. Bruno Jean-Marie Baillavoine
Mr. Bruno Jean-Marie Baillavoine
Independent Director
Independent Director
199.00
--
Mr. John Cipriano
Mr. John Cipriano
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Mario Gobbo, Ph.D.
Mr. Mario Gobbo, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel H. Zimmerman, Ph.D.
Dr. Daniel H. Zimmerman, Ph.D.
Senior Vice President - Research, Cellular Immunology
Senior Vice President - Research, Cellular Immunology
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Geert R. Kersten, Esq.
Mr. Geert R. Kersten, Esq.
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
41.35K
+1.87%
Ms. Patricia B. Prichep
Ms. Patricia B. Prichep
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
8.87K
+6.15%
Dr. Eyal Talor, Ph.D.
Dr. Eyal Talor, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
4.50K
+8.36%
Mr. Robert Eugene (Bob) Watson
Mr. Robert Eugene (Bob) Watson
Independent Chairman of the Board
Independent Chairman of the Board
814.00
--
Mr. Bruno Jean-Marie Baillavoine
Mr. Bruno Jean-Marie Baillavoine
Independent Director
Independent Director
199.00
--
Mr. John Cipriano
Mr. John Cipriano
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sat, May 17
Update time: Sat, May 17
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
2.58%
Kersten (Geert R)
1.36%
Gwn Securities Inc
1.31%
BlackRock Institutional Trust Company, N.A.
0.86%
Geode Capital Management, L.L.C.
0.83%
Other
93.06%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
2.58%
Kersten (Geert R)
1.36%
Gwn Securities Inc
1.31%
BlackRock Institutional Trust Company, N.A.
0.86%
Geode Capital Management, L.L.C.
0.83%
Other
93.06%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
4.55%
Investment Advisor
3.36%
Individual Investor
2.04%
Hedge Fund
0.26%
Research Firm
0.08%
Other
89.71%
Institutional Shareholding
Update time: Mon, Feb 24
Update time: Mon, Feb 24
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
139
8.58M
10.31%
-1.09M
2024Q4
154
8.90M
11.54%
-654.04K
2024Q3
159
7.92M
12.84%
-1.82M
2024Q2
170
8.27M
15.20%
-2.00M
2024Q1
223
9.54M
17.62%
-953.00K
2023Q4
231
8.54M
17.00%
-1.14M
2023Q3
241
7.38M
15.57%
-2.53M
2023Q2
252
7.44M
15.71%
-2.96M
2023Q1
267
7.49M
17.10%
-3.36M
2022Q4
277
7.75M
17.75%
-4.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
2.37M
2.96%
-40.66K
-1.69%
Dec 31, 2024
Kersten (Geert R)
1.24M
1.55%
+22.79K
+1.87%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
785.34K
0.98%
+15.92K
+2.07%
Dec 31, 2024
Geode Capital Management, L.L.C.
572.48K
0.71%
-40.38K
-6.59%
Dec 31, 2024
MAI Capital Management, LLC
159.60K
0.2%
+159.60K
--
Dec 31, 2024
Osaic Holdings, Inc.
432.13K
0.54%
--
--
Dec 31, 2024
Prichep (Patricia B)
266.23K
0.33%
+15.43K
+6.15%
Mar 31, 2025
Two Sigma Investments, LP
81.59K
0.1%
-43.21K
-34.62%
Dec 31, 2024
State Street Global Advisors (US)
215.21K
0.27%
+21.70K
+11.21%
Dec 31, 2024
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
